Dr. Julie Shaw


Dr. Julie Shaw
Head, Division of Biochemistry Director, Point of Care Testing The Ottawa Hospital and EORLA Academic Title and Associate Professor, Department of Pathology and Laboratory Medicine

Office: 613-737-8899 ext. 75175
Work E-mail: julshaw@eorla.ca



Dr. Shaw completed her BSc in Life Sciences and MSc in Pathology and Molecular Medicine at Queen’s University prior to completing her PhD in Laboratory Medicine and Pathobiology at the University of Toronto.  She then travelled to Edinburgh Scotland in the UK to complete a Post-doctoral Fellowship at the MRC Centre for Reproductive Health at the University of Edinburgh.  Dr. Shaw returned to Toronto in 2010 to complete her Fellow training in Clinical Biochemistry at The University of Toronto.  She then moved to Ottawa to join the Division of Biochemistry at The Ottawa Hospital in 2012.  Dr. Shaw became the Director of the Point of Care Testing (POCT) Program at The Ottawa Hospital in 2015 and the Division Head for Biochemistry in 2017. 

Dr. Shaw chairs the Special Interest Group for POCT of the Canadian Society for Clinical Chemists (CSCC) and is the CSCC representative on the International Federation of Clinical Chemistry (IFCC) POCT Working group. 

Research Interests

Dr. Shaw’s research interests are related to Quality Assurance and POCT.  POCT refers to diagnostic testing performed near to the patient, often at the patient bedside.  These tests are typically performed by non-laboratory trained clinical staff.  It is essential that quality assurance practices are in place to ensure quality of POCT while considering demands on clinical staff on busy clinical units. 


Selected Publications

Dr. Shaw was guest editor of a special issue of Practical Laboratory Medicine, focused on quality assurance practices related to POCT. 

Click the link to this special issue here:  https://www.sciencedirect.com/journal/practical-laboratory-medicine/special-issue/102ZFPCM83Z


  • Shaw, JLV, Deslandes V, Smith JE and Desjardins M.  (2021).  Evaluation of the Abbott PanbioTM COVID-19 Ag Rapid Antigen Test for the Detection of SARS-CoV-2 in Asymptomatic Canadians.  Diagnostic Microbiology and Infectious Disease.  In press.
  • Shaw JLV (2021)  Point-of-Care Testing:  The Good, the Bad, and the Laboratory Oversight. Journal of Applied Laboratory Medicine.  6:  1090-1093.
  • Venner AA, Beach LA, Shea JL, Knauer MJ, Huang Y, Fung AWS, Dalton J, Provencal M, Shaw JLV.  (2021).  Quality assurance practices for point of care testing programs:  Recommendations by the Canadian Society of Clinical Chemists point of care testing interest group.  Clinical Biochemistry.  88:  11-17
  • Shaw et al. (2020)  Effective interventions to improve the quality of critically high point-of-care glucose meter results.  Practical Laboratory Medicine.  e-pub article e00184.
  • Yip PM, Venner AA, Shea J, Fuezery A, Huang Y, Massicotte L, Tetrault N, Tomalty C, Shaw JLV.  (2018)  Point-of-care-testing:  A position statement from the Canadian Society of Clinical Chemists.  Clinical Biochemistry.  53:  156-159
  • Shaw JLV (2015)  Practical Challenges Related to Point of Care Testing.  Practical Laboratory Medicine. 9:  22-29.





Back to top